期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/ijms222111899
关键词
sulfonylurea receptor; edema; cellular swelling; traumatic brain injury; stroke; SUR 1; TRPM4; clinical trials
资金
- National Institute of Neurological Disorders and Stroke (NINDS) [K23NS101036, R01NS115815]
- Barrow Neurological Foundation
- Department of Veterans Affairs [I01RX003060, 1I01BX004652]
- Department of Defense [SC170199]
- National Heart, Lung and Blood Institute [R01HL082517]
- NINDS [R01NS102589, R01NS105633]
SUR1, a member of the ABC protein superfamily, is a key mediator of CNS cellular swelling through the TRPM4 channel. Inhibition of SUR1-TRPM4 pathway has shown promising results in reducing cerebral edema and hemorrhage across a range of CNS diseases.
Sulfonylurea receptor 1 (SUR1) is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) protein superfamily, encoded by Abcc8, and is recognized as a key mediator of central nervous system (CNS) cellular swelling via the transient receptor potential melastatin 4 (TRPM4) channel. Discovered approximately 20 years ago, this channel is normally absent in the CNS but is transcriptionally upregulated after CNS injury. A comprehensive review on the pathophysiology and role of SUR1 in the CNS was published in 2012. Since then, the breadth and depth of understanding of the involvement of this channel in secondary injury has undergone exponential growth: SUR1-TRPM4 inhibition has been shown to decrease cerebral edema and hemorrhage progression in multiple preclinical models as well as in early clinical studies across a range of CNS diseases including ischemic stroke, traumatic brain injury, cardiac arrest, subarachnoid hemorrhage, spinal cord injury, intracerebral hemorrhage, multiple sclerosis, encephalitis, neuromalignancies, pain, liver failure, status epilepticus, retinopathies and HIV-associated neurocognitive disorder. Given these substantial developments, combined with the timeliness of ongoing clinical trials of SUR1 inhibition, now, another decade later, we review advances pertaining to SUR1-TRPM4 pathobiology in this spectrum of CNS disease-providing an overview of the journey from patch-clamp experiments to phase III trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据